Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 156   

Articles published

MRK 56.26 +0.21 (0.37%)
price chart
Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences ...
While leader Gilead Sciences (NASDAQ: GILD ) waits on the FDA review for its combination of Sovaldi and levipasvir, and battles questions over Sovaldi's price tag, Merck is producing data on easy-to-treat populations and Bristol-Myers Squibb has turned ...
Related articles »  
One Put, One Call Option To Know About For Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the May ...
Related articles »  
Merck's Hepatitis C Drug Makes Important Progress
Merck & Co., Inc. (MRK) closed up 3.74% yesterday on news that it had made progress in the development of its hepatitis C combo therapies MK-5172 and MK-8742.
Related articles »  
Stocks to Watch Friday: Merck & Co., Inc., Deere & Company, and Toyota Motor ...
Momentum names that made notable moves on Thursday and could continue to do so into Friday's session include pharmaceutical firm Merck & Co., Inc. (NYSE:MRK), machinery concern Deere & Company (NYSE:DE), and automaker Toyota Motor Corp ...
Drug Most active stocks: Pfizer Inc. (NYSE:PFE), Merck & Co (NYSE:MRK ...  Gaining Green
Merck & Co. Price Target Increased to $70.00 by Analysts at MKM Partners ...  Ticker Report
Related articles »  
Merck & Co., Inc. (NYSE:MRK)'s Oncology Break-Through MK-3475 Said To ...
It is the case with the breakthrough drug from Merck & Co., Inc. (NYSE:MRK) called the MK-3475 that provides efficient results in the treatment of non-small cell lung cancer (NSCLC).
Related articles »  
Brand Face-Off: GlaxoSmithKline plc (ADR) vs. Merck & Co., Inc.
Pharmaceutical giants GlaxoSmithKline plc (ADR) (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) have charted different paths during the last year.
Insider Selling: Merck & Co. Insider Unloads 145225 Shares of Stock (MRK)  Ticker Report
Related articles »  
Merck & Co. Price Target Increased to $61.00 by Analysts at Jefferies Group (MRK)
Merck & Co., Inc. logo Equities research analysts at Jefferies Group boosted their price objective on shares of Merck & Co.
Related articles »  
Merck & Co., Inc. (NYSE:MRK) Presents Immunotherapy Findings; Collaborates ...
Boston, MA 04/07/2014 (wallstreetpr) - Yesterday, Merck & Co., Inc. (NYSE:MRK) provided early discoveries associated with the relation between PD-L1 Expression and the clinical outcome of its under study Anti-PD-1 Immunotherapy, MK-3475 at AACR ...
Related articles »  
Merck & Co. PT Raised to $70.00 at MKM Partners (MRK)
Merck & Co., Inc. logo Merck & Co. (NYSE:MRK) had its target price boosted by MKM Partners from $64.00 to $70.00 in a report issued on Friday, Analyst Ratings Network.
Merck & Co. CEO Kenneth Frazier Sells 10047 Shares (MRK)  Mideast Time
Related articles »  
Merck Hepatitis C combo pill impresses in Phase II
Merck's (MRK) two-drug combination pill for Hepatitis C stopped the virus in 43 out of 44 newly treated patients in a Phase II trial; there were also few major side effects.
Merck Data Show Potent Rival to Gilead's Hepatitis C Pill  Bloomberg
Merck: Hepatitis C drug has 98% cure rate in trial  MarketWatch
Related articles »